[1] |
Cramer JD, Burtness B, Ferris RL . Immunotherapy for head and neck cancer: recent advances and future directions[J]. Oral Oncol, 2019,99:104460.
doi: 10.1016/j.oraloncology.2019.104460
URL
pmid: 31683169
|
[2] |
Burtness B, Harrington KJ, Greil R , et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019,394(10212):1915-1928.
doi: 10.1016/S0140-6736(19)32591-7
URL
pmid: 31679945
|
[3] |
Ferris RL, Blumenschein G Jr, Fayette J , et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016,375(19):1856-1867.
doi: 10.1056/NEJMoa1602252
URL
pmid: 27718784
|
[4] |
Cohen EEW, Soulières D, Le Tourneau C , et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019,393(10167):156-167.
doi: 10.1016/S0140-6736(18)31999-8
URL
pmid: 30509740
|
[5] |
Seiwert TY, Burtness B, Mehra R , et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016,17(7):956-965.
doi: 10.1016/S1470-2045(16)30066-3
URL
pmid: 27247226
|
[6] |
Ferris RL, Blumenschein G Jr, Fayette J , et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol, 2018,81:45-51.
doi: 10.1016/j.oraloncology.2018.04.008
URL
pmid: 29884413
|
[7] |
Yearley JH, Gibson C, Yu N , et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer[J]. Clin Cancer Res, 2017,23(12):3158-3167.
doi: 10.1158/1078-0432.CCR-16-1761
URL
pmid: 28619999
|
[8] |
Rizvi NA, Hellmann MD, Snyder A , et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015,348(6230):124-128.
doi: 10.1126/science.aaa1348
URL
pmid: 25765070
|
[9] |
Lawrence MS, Stojanov P, Polak P , et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes[J]. Nature, 2013,499(7457):214-218.
doi: 10.1038/nature12213
URL
pmid: 23770567
|
[10] |
Gameiro SF, Ghasemi F, Barrett JW , et al. Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy[J]. Oncoimmunology, 2018,7(10):e1498439.
doi: 10.1080/2162402X.2018.1498439
URL
pmid: 30288365
|
[11] |
Harrington KJ, Ferris RL, Blumenschein G Jr , et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial[J]. Lancet Oncol, 2017,18(8):1104-1115.
doi: 10.1016/S1470-2045(17)30421-7
URL
pmid: 28651929
|
[12] |
Wang DY, Salem JE, Cohen JV , et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018,4(12):1721-1728.
doi: 10.1001/jamaoncol.2018.3923
URL
pmid: 30242316
|
[13] |
Johnson DB, Balko JM, Compton ML , et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016,375(18):1749-1755.
doi: 10.1056/NEJMoa1609214
URL
pmid: 27806233
|
[14] |
Di Giacomo AM, Danielli R, Guidoboni M , et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases[J]. Cancer Immunol Immunother, 2009,58(8):1297-1306.
doi: 10.1007/s00262-008-0642-y
URL
pmid: 19139884
|
[15] |
Chiou VL, Burotto M . Pseudoprogression and immune-related response in solid tumors[J]. J Clin Oncol, 2015,33(31):3541-3543.
doi: 10.1200/JCO.2015.61.6870
URL
pmid: 26261262
|
[16] |
Eisenhauer EA, Therasse P, Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009,45(2):228-247.
doi: 10.1016/j.ejca.2008.10.026
URL
|
[17] |
Baxi SS, Dunn LA, Burtness BA . Amidst the excitement: a cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma[J]. Oral Oncol, 2016,62:147-148.
doi: 10.1016/j.oraloncology.2016.10.007
URL
pmid: 27776933
|
[18] |
Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria[J]. Clin Cancer Res, 2009,15(23):7412-7420.
doi: 10.1158/1078-0432.CCR-09-1624
URL
pmid: 19934295
|
[19] |
Seymour L, Bogaerts J, Perrone A , et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017,18(3):e143-e152.
doi: 10.1016/S1470-2045(17)30074-8
URL
pmid: 28271869
|
[20] |
Tazdait M, Mezquita L, Lahmar J , et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria[J]. Eur J Cancer, 2018,88:38-47.
doi: 10.1016/j.ejca.2017.10.017
URL
pmid: 29182990
|
[21] |
Le Lay J, Jarraya H, Lebellec L , et al. irRECIST and iRECIST: the devil is in the details[J]. Ann Oncol, 2017,28(7):1676-1678.
doi: 10.1093/annonc/mdx168
URL
pmid: 28383646
|
[22] |
Xiang JJ, Uy NF, Minja FJ , et al. Hyperprogression after one dose of nivolumab in sinonasal cancer: a case report[J]. Laryngoscope, 2020,130(4):907-910.
doi: 10.1002/lary.28042
URL
pmid: 31058321
|
[23] |
Champiat S, Dercle L, Ammari S , et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017,23(8):1920-1928.
doi: 10.1158/1078-0432.CCR-16-1741
URL
pmid: 27827313
|
[24] |
Saâda-Bouzid E, Defaucheux C, Karabajakian A , et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J]. Ann Oncol, 2017,28(7):1605-1611.
doi: 10.1093/annonc/mdx178
URL
pmid: 28419181
|
[25] |
Keam SJ . Toripalimab: first global approval[J]. Drugs, 2019,79(5):573-578.
doi: 10.1007/s40265-019-01076-2
URL
pmid: 30805896
|
[26] |
Tang B, Yan X, Sheng X , et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients[J]. J Hematol Oncol, 2019,12(1):7.
doi: 10.1186/s13045-018-0693-2
URL
pmid: 30642373
|
[27] |
Sheng X, Yan X, Chi Z , et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase Ⅰb trial[J]. J Clin Oncol, 2019,37(32):2987-2999.
doi: 10.1200/JCO.19.00210
URL
pmid: 31403867
|
[28] |
Wang F, Wei XL, Wang FH , et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ⅰb/Ⅱ clinical trial NCT02915432[J]. Ann Oncol, 2019,30(9):1479-1486.
doi: 10.1093/annonc/mdz197
URL
pmid: 31236579
|
[29] |
Hoy SM . Sintilimab: first global approval[J]. Drugs, 2019,79(3):341-346.
doi: 10.1007/s40265-019-1066-z
URL
pmid: 30742278
|
[30] |
Markham A, Keam SJ . Camrelizumab: first global approval[J]. Drugs, 2019,79(12):1355-1361.
doi: 10.1007/s40265-019-01167-0
URL
pmid: 31313098
|
[31] |
Chen X, Ma L, Wang X , et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210[J]. Cancer Biol Med, 2019,16(1):173-181.
doi: 10.20892/j.issn.2095-3941.2018.0172
URL
pmid: 31119058
|
[32] |
Lin C, Wang S, Xie W , et al. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway[J]. Oncotarget, 2016,7(37):59236-59244.
doi: 10.18632/oncotarget.10985
URL
pmid: 27494860
|
[33] |
Xu J, Zhang Y, Jia R , et al. Anti-PD-1 Antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019,25(2):515-523.
doi: 10.1158/1078-0432.CCR-18-2484
URL
pmid: 30348638
|